Akshay Nair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akshay Nair has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Denys Shay
Department of Anesthesia, Critical Care and Pain Medicine, Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
3 shared publications - Ravi Dhawan
Emory University School of Medicine, Atlanta, GA, USA
3 shared publications - Alexander Buckenham Boyle
Department of Orthopaedic Surgery, Auckland City Hospital, Auckland, New Zealand
1 shared publication - Anna Woodbury
Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA
1 shared publication - Mercy A. Udoji
Department of Anesthesiology and Pain Medicine, Atlanta Veterans Affairs Medical Center, Decatur, Georgia
1 shared publication
Latest Publications
- Open Access
- 11 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Optimizing Home-Based Auricular Vagus Nerve Stimulation for Pain, Function, and Inflammation in Veterans with Knee Osteoarthritis: Protocol for a Randomized Pilot Dose-Finding Study (Preprint)
BACKGROUND Knee osteoarthritis (KOA) is a leading cause of pain and disability among Veterans. Current nonsurgical treatments primarily target peripheral inflammation, often providing incomplete symptom relief. Transcutaneous auricular vagus nerve stimulation (taVNS) is a nonpharmacologic neuromodulation therapy with the potential to modulate both inflammatory and central pain pathways. However, the optimal dosing regimen and biologic effects of home-based taVNS in KOA remain unknown. OBJECTIVE This study aims to identify the optimal home-based taVNS dosing regimen by comparing improvements in pain and physical function between high-dose taVNS, low-dose taVNS, and corticosteroid injection (CSI), while also evaluating dose-dependent changes in inflammatory biomarkers in Veterans with KOA. METHODS This prospective, open-label, randomized, 3-arm pilot clinical trial will enroll 40 Veterans with symptomatic KOA from the Atlanta Veterans Affairs Health Care System. Participants will be randomized in a 3:3:2 allocation to receive high-dose taVNS (n=15), low-dose taVNS (n=15), or a single intra-articular CSI (n=10). Clinical outcomes will be assessed using the Pain, Enjoyment of Life and General Activity scale (PEG-3); Defense and Veterans Pain Rating Scale (DVPRS); Knee Injury and Osteoarthritis Outcome Score (KOOS), Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function, and the Central Sensitization Inventory. Peripheral blood samples will be collected to evaluate changes in inflammatory biomarkers. The primary outcomes are changes in PEG-3 and DVPRS scores and inflammatory biomarker concentrations following treatment. RESULTS At the time of manuscript submission, Emory Institutional Review Board approval has been obtained (Protocol # 2026P000226), though ClinicalTrials.gov registration is pending, and participant recruitment is yet to begin. Following trial registration, participant enrollment and data collection will proceed according to the study protocol. CONCLUSIONS This pilot trial will provide preliminary evidence regarding the clinical and biologic effects of home-based taVNS in Veterans with KOA and identify an optimal dosing regimen for future clinical trials. If successful, the findings may support the development of a home-based, nonpharmacologic treatment strategy targeting both inflammatory and central pain mechanisms in KOA. CLINICALTRIAL ClinicalTrials.gov (registration pending)
- 11 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessOptimizing Home-Based Auricular Vagus Nerve Stimulation for Pain, Function, and Inflammation in Veterans with Knee Osteoarthritis: Protocol for a Randomized Pilot Dose-Finding Study (Preprint)
BACKGROUND Knee osteoarthritis (KOA) is a leading cause of pain and disability among Veterans. Current nonsurgical treatments primarily target peripheral inflammation, often providing incomplete symptom relief. Transcutaneous auricular vagus nerve stimulation (taVNS) is a nonpharmacologic neuromodulation therapy with the potential to modulate both inflammatory and central pain pathways. However, the optimal dosing regimen and biologic effects of home-based taVNS in KOA remain unknown. OBJECTIVE This study aims to identify the optimal home-based taVNS dosing regimen by comparing improvements in pain and physical function between high-dose taVNS, low-dose taVNS, and corticosteroid injection (CSI), while also evaluating dose-dependent changes in inflammatory biomarkers in Veterans with KOA. METHODS This prospective, open-label, randomized, 3-arm pilot clinical trial will enroll 40 Veterans with symptomatic KOA from the Atlanta Veterans Affairs Health Care System. Participants will be randomized in a 3:3:2 allocation to receive high-dose taVNS (n=15), low-dose taVNS (n=15), or a single intra-articular CSI (n=10). Clinical outcomes will be assessed using the Pain, Enjoyment of Life and General Activity scale (PEG-3); Defense and Veterans Pain Rating Scale (DVPRS); Knee Injury and Osteoarthritis Outcome Score (KOOS), Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function, and the Central Sensitization Inventory. Peripheral blood samples will be collected to evaluate changes in inflammatory biomarkers. The primary outcomes are changes in PEG-3 and DVPRS scores and inflammatory biomarker concentrations following treatment. RESULTS At the time of manuscript submission, Emory Institutional Review Board approval has been obtained (Protocol # 2026P000226), though ClinicalTrials.gov registration is pending, and participant recruitment is yet to begin. Following trial registration, participant enrollment and data collection will proceed according to the study protocol. CONCLUSIONS This pilot trial will provide preliminary evidence regarding the clinical and biologic effects of home-based taVNS in Veterans with KOA and identify an optimal dosing regimen for future clinical trials. If successful, the findings may support the development of a home-based, nonpharmacologic treatment strategy targeting both inflammatory and central pain mechanisms in KOA. CLINICALTRIAL ClinicalTrials.gov (registration pending)
- 26 September 2024
- Published by Elsevier in The Spine Journal
- Vol. 25 (1) , 55-58
Increasing venture capital investment in spinal surgery: an analysis of investments from 2000 to 2023
- 26 September 2024
- Published by Elsevier in The Spine Journal
- Vol. 25 (1) , 55-58
Increasing venture capital investment in spinal surgery: an analysis of investments from 2000 to 2023
- 7 February 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 90, 47-48
Generative artificial intelligence in surgery: balancing innovation with ethical challenges
- 7 February 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 90, 47-48
Generative artificial intelligence in surgery: balancing innovation with ethical challenges
- 2 February 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 90, 21-22
Cross-sectoral strategies for managing AI-driven content in plastic surgery
- 2 February 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 90, 21-22
Cross-sectoral strategies for managing AI-driven content in plastic surgery